Aidi Pharmaceuticals: Stock issuance in progress, future performance expected to improve and expand into overseas markets

Log in to the Sina Finance app, search for 【information disclosure】 to view more assessment levels

Investor Q&A:

May I ask, when will the company issue additional shares? What will the company’s performance look like in the future? Who are the company’s main overseas competitors? Thank you

Board Secretary Response (Aiding Pharmaceutical SH688488):

Dear investors, hello. The related matters concerning the company’s issuance of shares to specific targets are being advanced through the relevant procedures in accordance with the market environment and regulatory requirements. Specific progress will be strictly disclosed in accordance with laws and regulations. As for future performance, the company will continue to focus on its dual-engine strategy of innovative anti-HIV drugs and human protein. In 2025, the company’s combined sales revenue for HIV new drugs will be approximately RMB 284.38M, up 89.72% year over year, and the commercialization process shows a positive momentum. At the same time, by acquiring minority shareholder equity in Nanjing University Pharmaceutical, the company further integrates resources along the human protein industry chain. Nanjing University Pharmaceutical’s single-entity revenue will be RMB 303.38M, and net profit will be RMB 60.7M. Synergy effects will gradually emerge, supporting the company’s overall business performance to develop positively. In terms of overseas markets, the global anti-HIV drug market is dominated by internationally well-known pharmaceutical companies. The main competitors include Gilead and GlaxoSmithKline (GSK), whose integrase inhibitor products occupy a dominant position in the market. The company is actively expanding its internationalization strategy. ACC017, a single-pill formulation independently developed by the company, an ACC017 tablet that is the fastest-progressing domestically developed novel integrase inhibitor, has entered Phase III clinical trials. Its triple fixed-dose combination formulation ADC118 was also approved for clinical trials in October 2025. At present, the company has initiated communication with the U.S. FDA and relevant cooperation partners. The company plans to advance overseas clinical trials by conducting international multi-center clinical studies. The core objective is to complete the overseas NDA submission with the United States as the primary target and strive to obtain approval for marketing, gradually achieving overseas market penetration and share expansion, thereby supporting the implementation of the company’s internationalization strategy and a substantive breakthrough in its overseas business. The company will continue to deepen the commercialization operation of its core products, optimize resource allocation, and strive to improve operating performance to create long-term value for investors. Thank you for your attention to the company!

View more Q&A with the board secretary>>

Disclaimer: This information has been excerpted from publicly available information by Sina Finance and does not constitute any investment advice. Sina Finance does not guarantee the accuracy of the data; the content is provided for reference only.

A vast amount of information and precise interpretation—available on the Sina Finance app